Non-Hodgkin’s lymphoma (NHL) survivors can indeed face lifelong neurological risks, which arise from a complex interplay of the disease itself, its treatments, and immune-related complications. These neurological issues may persist long after remission and significantly affect survivors’ quality of life.
NHL is a type of cancer that originates in the lymphatic system, and while it primarily involves lymph nodes and lymphoid tissues, it can have far-reaching effects on the nervous system. Neurological complications in NHL survivors can be broadly categorized into direct effects of the lymphoma, treatment-related neurotoxicity, paraneoplastic syndromes, and metabolic or immune-mediated dysfunction.
**Direct neurological involvement** occurs when lymphoma cells invade the central nervous system (CNS) or peripheral nerves. Although CNS involvement is relatively rare, it can lead to serious conditions such as lymphoma relapse in the brain or spinal cord, causing symptoms like headaches, seizures, cognitive changes, or motor deficits. Peripheral nerve infiltration by lymphoma cells can cause sensory and motor neuropathies, leading to weakness, numbness, or pain in the limbs.
**Treatment-related neurotoxicity** is a major contributor to long-term neurological risks in NHL survivors. Chemotherapy agents, especially those used in NHL protocols, can cause peripheral neuropathy, often described as tingling, burning, or numbness in the hands and feet. This “chemo brain” phenomenon also includes cognitive impairments such as memory loss, difficulty concentrating, and slowed thinking, which may persist for months or years after treatment. Radiation therapy to areas near the brain or spinal cord can cause delayed neurological damage, including cognitive decline and motor dysfunction. Immunotherapy and newer targeted treatments, while promising, also carry risks of neurotoxicity, sometimes manifesting as immune effector cell–associated neurotoxicity syndrome (ICANS), which can cause confusion, seizures, or coma in severe cases.
**Paraneoplastic neurological syndromes (PNS)** represent another important cause of neurological complications in NHL survivors. These syndromes occur when the immune system, activated against lymphoma cells, mistakenly attacks components of the nervous system. PNS can cause a wide range of neurological problems, including sensory and motor neuropathies, cerebellar degeneration (leading to coordination problems), and limbic encephalitis (affecting memory and behavior). Guillain-Barré syndrome (GBS), an acute inflammatory demyelinating condition causing rapid muscle weakness and paralysis, has been reported as a rare initial manifestation or complication of NHL. These immune-mediated syndromes can be severe and sometimes progressive, requiring prompt diagnosis and treatment to prevent permanent damage.
**Metabolic and systemic factors** related to NHL and its treatment can further exacerbate neurological risks. Cancer and its therapies can disrupt metabolic balance, leading to conditions such as hyponatremia (low sodium), hypercalcemia (high calcium), or vitamin deficiencies, all of which can cause confusion, seizures, or neuropathic symptoms. Chronic inflammation and immune activation in lymphoma survivors may also contribute to ongoing neuroinflammation, increasing vulnerability to neurological injury.
The neurological risks faced by NHL survivors are often lifelong because some damage—especially to nerves and brain tissue—may be irreversible. Even after successful treatment and remission, survivors may experience persistent neuropathic pain, cognitive difficulties, or motor impairments. These complications can affect daily functioning, employment, and mental health, underscoring the need for ongoing neurological monitoring and supportive care.
Emerging diagnostic tools such as advanced brain imaging, electrophysiological studies, and cerebrospinal fluid biomarkers are improving the ability to detect and monitor neurological damage in NHL survivors. Early recognition of neurological symptoms and metabolic imbalances is critical to managing these risks effectively. Interventions may include physical therapy, medications for neuropathic pain, cognitive rehabilitation, and treatment of underlying metabolic or immune causes.
In summary
